|
 |
|
 |
|
| Licensing Executives Society (U.S.A. and Canada) Announces
2011 Deals of Distinction™ Awards
|
|
  |
|
|
"The 5th Japan
Bio-Venture Award"
Award by Minister of Education, Culture, Sports, Science and Technology.
|
|
|
|
| |
|
| |
| |
|
| Oncolys is seeking partnering opportunities for our lead compounds. For more information visit our Partnering opportunities page on this site or contact us at anticancer@oncolys.com |
|
|
|
|
|
|
 |
Oncolys BioPharma is a privately held biopharmaceutical company focused on the development of novel biologics for the treatment of cancer and infectious disease.
We believe that through the development of replication-competent oncolytic virus and micrometastatic tumor diagnostic viruses, we produce safer, more effective, QOL-improving approaches aiming to revolutionize the current mode of cancer therapy.
Oncolys completed Phase-I clinical trial for Telomelysin, a replication-competent oncolytic virus, in the U.S. and plan to initiate Phase-I/II clinical study in Taiwan in collaboration with Medigen Biotechnology Corp. In addition to Telomelysin, Oncolys in-licensed oncology pipeline, YM753 (Oncolys code name: OBP-801) which has the potential to become best-in-class histone deacetylase (HDAC) inhibitor. Oncolys is conducting additional enabling preclinical studies and formulation development to file an IND.
Oncolys inlicensed exclusive worldwide rights of Festinavir, best-in-class potential NRTI from Yale University and completed phase Ia in the US and phase Ib/IIa clinical study in France. With a promising clinical safety and efficacy data obtained at phase Ib/IIa study, Oncolys succeeded to conclude an exclusive worldwide licensing agreement with Bristol-Myers Squibb. In addition to Festinavir, Oncolys antiviral pipeline includes a new class of anti-hepatitic-C-virus (HCV) agent in early research stage having new mechanism of action.
As a diagnostic/tumor marker agent, Oncolys is currently developing TelomeScan® (OBP-401), which is at feasibility assessment stage and is expected to be a first and best-in-class diagnostic agent in detecting various types of living and circulating tumor cells (CTC) in the blood.
|
|
 |
|
|
|
|
|
|
